Author

Andrew W Boyd

Queensland Institue of Medical Research - Cited by 15,063

Biography

Andrew W Boyd is a well-known researcher working in Department of Haemotology and oncology and has extended valuable service for many years and has been a recipient of many awards and grants.  
Title
Cited by
Year
A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia
SZ He, S Busfield, DS Ritchie, MS Hertzberg, S Durrant, ID Lewis, ...Leukemia & lymphoma 56 (5), 1406-1415, 2015201
125
2015
A reference collection of patient-derived cell line and xenograft models of proneural, classical and mesenchymal glioblastoma
BW Stringer, BW Day, RCJ D’Souza, PR Jamieson, KS Ensbey, ZC Bruce, ...Scientific reports 9 (1), 4902, 2019201
119
2019
Extracellular vesicles released by glioblastoma cells stimulate normal astrocytes to acquire a tumor-supportive phenotype via p53 and MYC signaling pathways
S Hallal, DM Mallawaaratchy, H Wei, S Ebrahimkhani, BW Stringer, ...Molecular neurobiology 56, 4566-4581, 2019201
87
2019
Understanding the uptake of nanomedicines at different stages of brain cancer using a modular nanocarrier platform and precision bispecific antibodies
ZH Houston, J Bunt, KS Chen, S Puttick, CB Howard, NL Fletcher, ...ACS central science 6 (5), 727-738, 2020202
36
2020
Nuclear factor one B (NFIB) encodes a subtype-specific tumour suppressor in glioblastoma
BW Stringer, J Bunt, BW Day, G Barry, PR Jamieson, KS Ensbey, ...Oncotarget 7 (20), 29306, 2016201
34
2016
Anti-GD2-ch14. 18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and …
A Tivnan, T Heilinger, JM Ramsey, G O’Connor, JL Pokorny, JN Sarkaria, ...Oncotarget 8 (10), 16605, 2017201
32
2017
Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosis-protein antagonist birinapant
Z Zakaria, A Tivnan, L Flanagan, DW Murray, M Salvucci, BW Stringer, ...British journal of cancer 114 (2), 188-198, 2016201
30
2016
EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia
S Charmsaz, F Al-Ejeh, TM Yeadon, KJ Miller, FM Smith, BW Stringer, ...Leukemia 31 (8), 1779-1787, 2017201
29
2017
EphA2 as a diagnostic imaging target in glioblastoma: a positron emission tomography/magnetic resonance imaging study
S Puttick, BW Stringer, BW Day, ZC Bruce, KS Ensbey, K Mardon, ...Molecular imaging 14 (6), 70.2015. 00008, 2015201
29
2015
Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors
S Charmsaz, AM Scott, AW BoydExperimental hematology 54, 31-39, 2017201
25
2017
Digenic inheritance of mutations in EPHA2 and SLC26A4 in Pendred syndrome
M Li, S Nishio, C Naruse, M Riddell, S Sapski, T Katsuno, T Hikita, ...Nature communications 11 (1), 1343, 2020202
25
2020
EphA3 pay-loaded antibody therapeutics for the treatment of glioblastoma
C Offenhäuser, F Al-Ejeh, S Puttick, KS Ensbey, ZC Bruce, PR Jamieson, ...Cancers 10 (12), 519, 2018201
24
2018
EphA4-Fc treatment reduces ischemia/reperfusion-induced intestinal injury by inhibiting vascular permeability
TM Woodruff, MCL Wu, M Morgan, NT Bain, A Jeanes, J Lipman, MJ Ting, ...Shock: Injury, Inflammation, and Sepsis: Laboratory and Clinical Approaches …, 2016201
23
2016
EphA2 is a therapy target in EphA2-positive leukemias but is not essential for normal hematopoiesis or leukemia
S Charmsaz, K Beckett, FM Smith, C Bruedigam, AS Moore, F Al-Ejeh, ...PloS one 10 (6), e0130692, 2015201
22
2015
The dystroglycan receptor maintains glioma stem cells in the vascular niche
BW Day, JD Lathia, ZC Bruce, RCJ D’Souza, U Baumgartner, KS Ensbey, ...Acta neuropathologica 138, 1033-1052, 2019201
22
2019
Decreased signalling of EphA4 improves functional performance and motor neuron survival in the SOD1G93A ALS mouse model
J Zhao, LT Cooper, AW Boyd, PF BartlettScientific Reports 8 (1), 11393, 181
20
2018
Dianthin-30 or gelonin versus monomethyl auristatin E, each configured with an anti-calcitonin receptor antibody, are differentially potent in vitro in high-grade glioma cell …
R Gilabert-Oriol, SGB Furness, BW Stringer, A Weng, H Fuchs, BW Day, ...Cancer Immunology, Immunotherapy 66, 1217-1228, 2017201
19
2017
EphA4 Regulates Hippocampal Neural Precursor Proliferation in the Adult Mouse Brain by d-Serine Modulation of N-Methyl-d-Aspartate Receptor Signaling
J Zhao, CJ Taylor, EA Newcombe, MD Spanevello, I O’Keeffe, LT Cooper, ...Cerebral Cortex 29 (10), 4381-4397, 2019201
14
2019
Glycoengineering of EphA4 Fc leads to a unique, long-acting and broad spectrum, Eph receptor therapeutic antagonist
CL Pegg, LT Cooper, J Zhao, M Gerometta, FM Smith, M Yeh, PF Bartlett, ...Scientific Reports 7 (1), 6519, 2017201
14
2017
Q-Cell glioblastoma resource: proteomics analysis reveals unique cell-states are maintained in 3D culture
RCJ D’Souza, C Offenhäuser, J Straube, U Baumgartner, A Kordowski, ...Cells 9 (2), 267, 2020202
13
2020

Referred From: https://scholar.google.com.au/citations?user=a4ZbNDoAAAAJ&hl=en

Cited by
Citations 15063
h-index 67
i10-index 168
Recommended Journals
Open Access Journals